{
    "title": "US FDA approves Regeneron's ultra-rare blood disease drug",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12421979/US-FDA-approves-Regenerons-ultra-rare-blood-disease-drug.html",
    "date": "2023-08-18",
    "keywords": [
        "drug",
        "disease",
        "company",
        "eylea",
        "approval",
        "pratik",
        "jain",
        "veopoz",
        "year",
        "treatment",
        "gene",
        "mechanism",
        "veopozs",
        "inspection",
        "dose",
        "version",
        "friday",
        "health",
        "regulator",
        "blood",
        "pozelimab",
        "adult",
        "age",
        "food",
        "administration",
        "lifethreatening",
        "price",
        "singleuse",
        "vial",
        "response",
        "quarter",
        "regeneron",
        "bodys",
        "regulation",
        "body",
        "warning",
        "infection",
        "marketing",
        "application",
        "blockbuster",
        "eye",
        "aflibercept",
        "decision",
        "franchise",
        "highdose",
        "capital",
        "analyst",
        "seigerman",
        "market",
        "fda",
        "june",
        "manufacturer",
        "catalent",
        "reporting",
        "vaibhav",
        "sadhamta",
        "khushi",
        "mandowara",
        "bengaluru",
        "editing",
        "shilpi",
        "majumdar"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}